Summary Objective: To determine whether initiation of maintenance treatment with the salmeterol (S)/fluticasone propionate (FP) combination (Seretidet/Vianit/ Advairt) is more effective than inhaled steroid alone in patients with asthma symptomatic on short-acting bronchodilator alone.
Introduction
The goal of asthma management is to achieve and maintain disease control. With effective treatment that targets the underlying components of asthma, patients should be able to lead a normal active life with a minimum of asthma symptoms.
Inhaled corticosteroids (ICS) and long-acting b 2 -agonists (LABA) have complementary modes of action to treat the underlying components of asthma. Therefore, it is reasonable to expect that combination treatment can offer greater asthma control than monotherapy. The Global INitiative for Asthma treatment (GINA) Guidelines recommend a step-wise approach to asthma treatment. 1 According to GINA Guidelines, an asthmatic patient has persistent asthma if a short-acting bronchodilator is used 1 or more times a week. 1 The stepwise approach to treatment of asthma prescribes the initiation of maintenance treatment with ICS together with a short-acting bronchodilator as needed (mild asthma). If low dose ICS fails to control asthma symptoms addition of a long-acting inhaled bronchodilator is recommended (moderate-severe asthma). 1 Many studies have shown that the addition of a LABA improves asthma control more than doubling the dose of ICS for symptomatic patients with moderate and severe asthma inadequately controlled on their current ICS dose. [2] [3] [4] [5] [6] This has also been confirmed in a meta-analysis. 7 The positive results are reflected in the GINA Guidelines that recommend adding a LABA as a preferred option to increasing the ICS dose in patients who remain symptomatic on low-medium dose ICS. 1 By initiation of maintenance treatment asthma patients may also benefit from adding a LABA to the ICS. However, only few studies have evaluated initial maintenance treatment options, specifically ICS with a LABA in patients with asthma who had not previously been treated with ICS.
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Results from a pilot study by Pearlman et al. 8 indicate that patients who are symptomatic on 'asneeded' bronchodilators alone can derive greater benefits from the concurrent use of salmeterol and low dose ICS than inhaled ICS alone upon initiation of maintenance asthma therapy. This was, however, a study without a pre-defined primary efficacy parameter. This is the first study with the objective to determine whether initiation of maintenance treatment with the salmeterol/fluticasone propionate (S/FP) combination (Seretidet) is more effective in improving daily asthma control than initiation of monotherapy with FP (Flixotidet) alone in patients with persistent asthma symptomatic when treated with only a short-acting bronchodilator, also for mild persistent asthma.
Methods

Study design
This study was conducted as a randomised, controlled, double-blind, parallel-group, comparative multi-centre study conducted in 45 centres in Denmark (44 general practices and 1 hospital department). After a 2-week baseline period patients were randomised to treatment for 24 weeks with either S/FP 50/100 mg bd or FP 100 mg bd, both delivered via the Diskust. Patients had 4 study visits at the clinic: visit 1 (screening), visit 2 (randomisation), visit 3 (after 12 weeks treatment), and visit 4 (after 24 weeks treatment).
Patients were allowed to use salbutamol prn for symptom relief during the entire study period.
Study population
Male and female patients were eligible for the study if they were at least 18 years of age, had an asthma diagnosis as defined by the American Thoracic Society, 9 and used a short-acting bronchodilator once or more per week for relief of asthma symptoms within 2 months prior to enrolment and during the baseline period. According to the GINA Guidelines they had persistent asthma. The asthma diagnosis had to be confirmed in the clinical record for X3 months. The baseline diurnal peak expiratory flow (PEF) variation had to be X20% or one of the following determined within 3 years prior to baseline: (a) FEV 1 reversibility X15% in response to bronchodilator (b) PC 20 metacholine p4 mg/ml (c) diurnal PEF variation X20%. Female patients were required to have a negative pregnancy test. Patients were excluded if they experienced an asthma exacerbation during the 2-week baseline period.
Use of long-acting bronchodilators, ICS, or other long-acting asthma medication were not allowed within 2 months prior to visit 1. Use of oral/ parenteral corticosteroid therapy was not allowed within 1 month prior to visit 1 but allowed between visit 2 and 4.
Use of asthma medication other than study drug and salbutamol was not allowed in the baseline and treatment period of the study.
No other medication that might affect the course of asthma or interfere with the study results was permitted.
Patients were excluded from the study if they had an upper or lower respiratory tract or middle ear infection within 1 month prior to visit 1, serious cardiovascular disease, diabetes mellitus, untreated hypokalaemia, or thyrotoxicosis. In addition, they were excluded if they had a known or suspected hypersensitivity reaction to drug constituents, any other diseases that might interfere with the study results, or had problems operating the inhaler or peakflow meter.
Smoking history was categorised as smoker, exsmoker (stopped smoking before visit 1), or never smoked.
Measurements and evaluations
The primary efficacy parameter was the percentage of symptom-free 'day þ night's (24-h periods).
The following secondary efficacy parameters were evaluated: lung function (morning and evening PEF), symptoms (day symptom score, night symptom score, days and nights without symptoms), salbutamol use (number of episodes, 'day-þ night's without salbutamol), episode-free 'day þ night's (day symptom score ¼ 0, night symptom score ¼ 0, no salbutamol use, no exacerbations, no adverse events), exacerbations, and adverse events.
During the baseline and treatment periods patients completed diary cards each morning and evening recording the following information: morning and evening PEF, day and night symptom scores, and use of salbutamol prn for relief of symptoms. PEF was measured using a Mini-Wright s peakflow meter (Clement Clark) before study drug was taken. The highest value of 3 readings was recorded.
Day symptom score scale 0-5 (0 ¼ No symptoms during daytime, 1 ¼ Symptoms for a short period during daytime, 2 ¼ Symptoms for two or more short periods during daytime, 3 ¼ Symptoms for most of the day, which did not affect your normal daily activities, 4 ¼ Symptoms for most of the day, which affected your normal daily activities, 5 ¼ Symptoms so severe, that you were unable to work or perform your normal daily activities).
Night symptom score scale 0-4 (0 ¼ No symptoms during the night, 1 ¼ Symptoms causing you to wake up once or wake early, 2 ¼ Symptoms causing you to wake up twice or more (include waking up early), 3 ¼ Symptoms causing you to be awake for most of the night, 4 ¼ Symptoms so severe, that you were unable to sleep at all).
The investigator recorded adverse events at each clinic visit and rated the severity of the event and the perceived relationship of the event to the study drug. The investigator also recorded all concurrent medication and asthma exacerbations in the CRF at the clinic visits. A moderate asthma exacerbation was defined as a deterioration in asthma requiring administration of ICS over and above current study medication and/or oral corticosteroid and/or parenteral corticosteroid. A severe asthma exacerbation was defined as a deterioration in asthma requiring emergency hospital treatment. Oropharyngeal examination was performed at each visit.
Approval for the study was obtained from the Danish Medicines Agency and scientific ethics committees. All patients gave written informed consent before any study procedures were carried out.
The study was conducted in accordance with the principles of Good Clinical Practice.
Statistical analysis
All efficacy parameters were analysed on an intentto-treat basis and data from all patients with at least one dose of study drug were included in the analysis.
A sample size of 72 in each treatment group would have 90% power to detect a 20% difference in means in the percentage of symptom-free 'day-þ night's between treatment groups (assuming a common standard deviation of 37%).
Comparisons of the treatments were performed using analysis of variance (ANOVA). Due to baseline dependence (Po0:0001) data were analysed with baseline values as covariates.
All 95%-confidence intervals and all hypothesis tests were 2-sided and conducted using a 5% significance level.
The assessment period for efficacy analyses was defined as two weeks after start of treatment until end of treatment.
A sub-group analysis of patients with mild persistent asthma was performed for patients with a mean baseline morning PEFX80% of the predicted PEF. 1 Predicted normal values for lung function were from Quanjer et al. 10 
Results
Study population
A total of 221 patients were screened and 150 patients were randomised to study treatment. 71 patients were not randomised because they withdrew the consent (5), did not return to the clinic (8), did not complete the diary (2), were protocol violators or withdrawn by mistake (4), used salbutamol for relief of symptoms less than once per week (6), the diurnal PEF variation was o20% and they did not have a historical lung function test made within the last 3 years pre-study (38). 8 patients had other reasons for not being randomised.
Randomisation resulted in comparable treatment groups at baseline with respect to patient demographics and pulmonary function ( Table 1 ). The majority of the patients were randomised based on reversibility. Only 5 patients (3 in the S/FP group and 2 in the FP group) were randomised based on bronchial hyperreactivity.
132 patients completed the study, 67 (86%) in the S/FP group and 59 (82%) in the FP group. Reasons for withdrawals were comparable for the treatment groups (Table 2) .
Symptoms
Before initiation of maintenance treatment the patients experienced symptoms on most days. During the baseline period patients were only symptom-free on 25 and 20% 'day þ night's for the FP and S/FP group, respectively. Study treatments markedly increased the percentage of symptomfree 'day þ night's.
Patients receiving S/FP as initial maintenance treatment achieved a significantly higher percentage of symptom-free 'day þ night's compared to those receiving FP alone (Fig. 1) . S/FP gave an increase from 20% to 64% and FP from 24% to 51%. The treatment difference was 13.2% in favour of S/ FP (P ¼ 0:035). When adjusted for baseline, the treatment difference in favour of S/FP was 15.3% (P ¼ 0:008).
The sub-analysis of symptom-free 'day þ night's in patients classified with mild asthma (58% of the patients) also showed a statistically significant difference in favour of S/FP compared with FP alone (Fig. 1) . The treatment difference was 16.9%, P ¼ 0:025 (n ¼ 30 in S/FP group, n ¼ 44 in FP group).
Use of salbutamol prn for relief of symptoms S/FP was superior to FP alone in increasing the percentage of 'day þ night's (24-h periods) without salbutamol use prn, Po0:05 (Table 3) .
Lung function
Combination treatment with S/FP improved morning PEF (P ¼ 0:0011) and evening PEF (P ¼ 0:011) significantly more than monotherapy with FP (Table 3) .
Episode-free 'day þ night's
The percentage of episode-free 'day þ night's increased from 15% to 60% with S/FP compared with 17-47% with FP alone. The treatment Figure 1 Symptom-free 'day þ night's (24-h periods) before and after initiation of maintenance treatment with either S/FP 50/100 mg bd or FP 100 mg bd.
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difference of 14% was statistically significant in favour of S/FP (P ¼ 0:015) (Fig. 2) .
Asthma exacerbations
No difference in asthma exacerbations was observed between treatment groups. No patients experienced moderate exacerbations. Only 1 patient in each treatment group experienced a severe exacerbation.
Safety
The combined use of salmeterol with FP was not associated with additional safety risks compared with monotherapy with FP, as measured by frequency of adverse events. The safety profiles observed in the study were similar across treatment groups. 62% of patients in the S/FP group and 58% of patients in the FP group had at least one adverse event during the 24-weeks treatment. The most common adverse events were headaches (28%), common colds (8%), cough (7%), and back pain (5%). 1 patient in each treatment group had oral candidiasis. 1 patient in the S/FP group and 2 patients in the FP group had a serious adverse event. None of these serious adverse events was considered related to the study drug.
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Withdrawal from the study because of an adverse event occurred in 3 patients (1 treated with S/FP and 2 treated with FP).
Discussion
This was the first study designed primarily to determine whether initiation of maintenance treatment with the ICS þ LABA combination S/FP lead to better asthma control with more day and night's without symptoms of the disease than initiation of monotherapy with the ICS FP alone in patients with persistent asthma symptomatic on short-acting bronchodilator alone, also for mild persistent asthma. Asthma patients with milder asthma are typically treated in general practice. Among those treated with short-acting bronchodilators only, there might be a group of patients with under-treated asthma because of unrecognised severity or changes in the severity of the disease. The patients may be unaware of other treatment options or just accept the symptoms and therefore do not report the frequency or worsening of symptoms. Identification of patients not well-controlled is the first challenge to achieve better asthma control for this group of patients. The next is to choose the most effective treatment for the patient.
Results from this study showed that both study treatments markedly improved the asthma control and lung function, but patients benefit from significant greater improvements in asthma control and lung function by initiation of maintenance therapy with the combination treatment S/FP compared with the ICS FP alone.
Analysis of the primary efficacy parameter showed that patients receiving S/FP as initial maintenance treatment achieved a significantly higher percentage of symptom-free 'day þ night's than those receiving FP alone.
The sub-analysis of symptom-free 'day þ night's of patients classified with mild asthma also showed a statistically significant difference in favour of S/ FP compared with FP alone.
The analysis of secondary end-points for symptoms and use of rescue medication for relief of symptoms, also showing a statistically significant treatment difference, supported the conclusion of a treatment difference in favour of S/FP vs. FP monotherapy.
Findings from other studies conducted in patients with asthma symptomatic when previously treated with short-acting bronchodilators alone have been published. A 4-week pilot study compared S þ FP with FP alone, 8 two 12-week studies compared S/FP with FP, 11,12 a 4-week study of S/FP without comparator, 13 and two studies with formoterol and budesonide that included ICS-na. ıve as well as ICS-treated patients.
14,15 Symptoms were not the primary endpoint in any of these studies.
The 12-week studies comparing S/FP with FP alone differed from this study by allowing treatment with LABA up to 72 h before enrolment.
This study confirmed the preliminary finding by Pearlman et al. 8 Patients symptomatic on asneeded bronchodilators alone derived greater benefits from initiation of maintenance therapy with salmeterol and low dose ICS than ICS alone. The treatment difference was significant for the asthma symptom scores and percentage of days with no asthma symptoms.
A 12-week study comparing S/FP with FP alone also showed that S/FP treatment was significantly more effective than FP alone in improving the percentage of symptom-free days and days without use of rescue medication for patients with asthma not treated with ICS pre-study.
11
The S/FP 50/250 mg study without comparator 13 showed a baseline percentage of symptom-free days of 20% in patients with mild-moderate asthma which is similar to the percentage observed in this study. The percentage of symptom-free days increased to 70% after 4-weeks treatment with S/ FP. This is also very similar to the percentage of 66% seen in this study.
The significantly higher improvements in morning and evening PEF observed for patients who were treated with S/FP compared to FP alone are in line with findings from the pilot study with S þ FP 8 as well as the two 12-week studies with S/FP analysing lung function as the primary efficacy parameter. 11, 12 Two studies with formoterol and budesonide that included ICS-na. ıve as well as ICS-treated patients 14, 15 have been published. The primary endpoints in a 7-month study comparing budesonide þ formoterol with budesonide alone were the time to achieve asthma control and time to first asthma exacerbation.
14 Patients were allowed to use short-acting b 2 -agonist alone or with an ICS pre-study. 2/3 of the patients were treated with ICS pre-study, 1/3 were not. The treatment difference in favour of combination treatment vs. ICS alone was significant for the primary endpoints as well as for symptoms, rescue medication use, and lung function. It is concluded that combination treatment enabled asthma control to be achieved more quickly and in a greater proportion of patients, regardless of whether or not patients received ICS pre-study.
O'Byrne et al. 15 reported the results of a study in patients with mild asthma who pre-study experienced symptoms while either taking no ICS or lowdose ICS. The study was of longer duration and included a larger number of patients. The aim of the study was to determine whether regular treatment with low doses of budesonide, with or without low doses of formoterol, would reduce severe asthma exacerbations and improve asthma control (composite measure) compared with placebo. The patients were treated for 1 year. Symptoms, rescue medication use, and lung function were studied as secondary endpoints. In consistency with our study maintenance treatment with a low dose of ICS reduced the percentage of poorly controlled asthma days by more than half. A statistically significant difference in favour of combination treatment was shown for lung function. Improvement of all other outcome variables only achieved statistical significance for patients previously treated with ICS. This is not consistent with our findings showing that the sub-group of patients with mild persistent asthma had significantly better asthma control with combination therapy compared with ICS monotherapy. It is not possible to say if the differences in findings can be explained by differences in patient populations or drugs.
The importance of identification of under-treated patients with persistent asthma has been emphasised. Daily asthma control can be improved significantly by initiation of maintenance treatment.
The findings in this and other studies conducted with similar patients suggest that regular maintenance treatment of both inflammation and smooth muscle dysfunction may be necessary for the optimal management of asthma from an early stage in treatment.
The significant treatment difference in favour of combination treatment in the group of patients with mild persistent asthma is of importance because it suggests the consideration of an update to current asthma treatment guidelines to recommend initiation of maintenance combination treatment for mild persistent asthma.
In conclusion, S/FP 50/100 mg bd is significantly more effective than FP 100 mg bd alone when used as initial maintenance therapy in symptomatic asthma patients currently treated with short-acting bronchodilators alone, also for mild persistent asthma. The patients benefit from significant greater improvements in daily asthma control and lung function by initiation of maintenance therapy with the combination treatment S/FP compared with inhaled steroid (FP) alone.
